Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3082 in Advanced Solid Tumors with KRAS G12D Mutation
NCT05382559Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2022
- Primary completion
- Dec 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 7
01
Overview
Phase 1, open-label trial of setidegrasib in solid tumor, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) (11 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities up to 28 Days, Number of Participants with Adverse Events up to 48 months and 6 more. Started Jun 2022; status: recruiting.
02
Drugs
setidegrasib
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05382559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382559.